Morgan Stanley on Compass Pathways (CMPS): 'we view today’s update as incrementally encouraging'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
TD Cowen on Compass Pathways (CMPS) FDA Grant: 'meaningful positive and expected in light of last Saturday’s Executive Order'
April 24, 2026 3:41 PM EDTTD Cowen analyst Ritu Baral reiterated a Buy rating and $29.00 price target on Compass Pathways (NASDAQ: CMPS)
The analyst comments "Our View: We view the CPNV as a meaningful positive and expected in light of last Saturdays Executive Order accelerating development and access for psychedelicbased... More
Oppenheimer on Compass Pathways (CMPS) FDA Grant: 'reinforcing our conviction considering the earlier launch timeline for COMP360 in TRD'
April 24, 2026 1:24 PM EDTOppenheimer analyst Francois Brisebois reiterated an Outperform rating and $20.00 price target on Compass Pathways (NASDAQ: CMPS).
The analyst comments "We view FDA granting a CNPV with agreement on NDA rolling review as reinforcing our conviction considering the earlier launch timeline for COMP360 (psilocybin)... More
Compass Pathways receives FDA rolling review for psychedelic depression drug
April 24, 2026 10:37 AM EDTCompass Pathways plc (NASDAQ: CMPS) announced the U.S. Food and Drug Administration granted the company a rolling New Drug Application review for COMP360, its synthetic psilocybin treatment for treatment-resistant depression.
The FDA also selected COMP360 for the Commissioner's National Priority Voucher program. Companies in this program receive enhanced communications with the agency and a shortened... More
FDA advances psychedelic drug studies for mental health treatment
April 24, 2026 9:10 AM EDTThe Food and Drug Administration announced regulatory actions to support development of psychedelic medications for mental health conditions, following an executive order directing accelerated access to treatments for serious mental illness.
The agency issued national priority vouchers to three companies studying psilocybin for treatment-resistant depression and major depressive disorder, and methylone for post-traumatic stress disorder.
The FDA also approved an early phase clinical study of noribogaine... More
B.Riley Starts Compass Pathways (CMPS) at Buy
April 24, 2026 3:49 AM EDTB.Riley analyst Madison El-Saadi initiates coverage on Compass Pathways (NASDAQ: CMPS) with a Buy rating and a price target of $17.00.
The analyst comments "We are initiating coverage of Compass Pathways plc (CMPS) at Buy with a $17 PT heading into its second Ph3 durability readout (3Q26E) and rolling NDA submission (4Q26E). CMPS is on track to develop the first FDA-approved oral... More
